Mark Stroh Email and Phone Number
Mark Stroh work email
- Valid
- Valid
- Valid
Mark Stroh personal email
- Valid
Mark Stroh phone numbers
I am an experienced leader in Translational and Quantitative Clinical Pharmacology supporting pre-IND through Phase 3 and post-marketing development of small molecules, biologics, and novel formats across several disease areas including oncology, neurology, endocrine, cardiovascular, infectious disease, and rare disease. Where I excel:• Building and leading technical teams • Cross functional leadership• Model informed drug development• Driving successful INDs, NDAs, and BLAsHighlights:• Demonstrated record of team building and mentorship, with significant experience building new functions from the ground up • Champion of effective teamwork in developing a wide array of modalities, including small molecule, biologics, and novel format> Small Molecule: Key contributor to FIH-Phase 3, DDI, ADME, biopharmaceutic, and special population study protocols and CSRs.> Biologics: Both functional area lead and cross-functional accountable (Pharmacology Subteam Leader) roles for approval of TECENTRIQ® (atezolizumab) valued at $2.68 billion in 2023. > Novel Format: Functional area head for multiple monoclonal, ADC, and TCB prodrug INDs.> Novel format: Functional area head for the first ever systemically administered CRISPR therapies.Specialties:Cross-Disciplinary Leadership; Drug Development & Clinical Trials; Clinical Pharmacology; Translational Sciences; Team Building & Leadership; Model Informed Drug Development; Small Molecule Therapies; ADME; DDI; Special Populations; Biopharmaceutics; Biologics; Immunotherapies; Immunogenicity; Novel Format; Prodrugs; CRISPR; Genome Editing; Regulatory Interactions; IND; NDA/ BLA; Executive Presentations; Project & Vendor Management; Partnerships & Collaboration
Metsera
View-
Senior Vice President, PharmacologyMetsera May 2024 - Present
-
Vice President And Head, Clinical PharmacologyIntellia Therapeutics, Inc. Apr 2021 - Jan 2024Cambridge, Massachusetts, UsBuilt and led lead company’s first Quantitative Clinical Pharmacology department in support of multiple ex vivo and in vivo CRISPR therapies in rare disease and oncology. Capabilities of the department included clinical pharmacology, pharmacometrics, and QSP. Team utilized model informed drug development to facilitate advancement of the first ever systemically administered CRISPR-based therapies from pre-IND to first-in-human and subsequent pivotal studies. -
Vice President And Head, Clinical Pharmacology, Qsp, And PharmacometricsCytomx Therapeutics Nov 2016 - Mar 2021South San Francisco, Ca, UsFormed and led company’s first Quantitative Clinical Pharmacology department with capabilities that encompassed clinical pharmacology, QSP, and pharmacometrics. Team informed robust translation across the entire portfolio of first-of-kind antibody prodrug assets (i.e. monocolonal, ADC, and TCB prodrugs) using a common model-based approach in the absence of prior clinical experience with this platform. Proponent of effective teamwork for data analysis plans, biomarker programs, study protocols, and regulatory documents. -
Senior Scientist, Clinical PharmacologyGenentech Oct 2012 - Oct 2016South San Francisco, California, UsProvided direct and supervisory support of multiple assets in oncology and infectious disease with later emphasis in cancer immunotherapy. Both Clinical Pharmacology lead and Pharmacology Subteam Lead for first approval of TECENTRIQ® (atezolizumab). Formulated successful Clinical Pharmacology strategy for development of multiple cancer immunotherapy assets role as Clinical Pharmacology and Modeling and Simulation Therapeutic Area Lead for the broader cancer immunotherapy therapeutic area. Managed team with Ph.D. and M.S./B.S. level staff. -
Senior Investigator, Clinical Pk/PdMerck Nov 2004 - Jun 2011Provided supervisory and direct support for preclinical to late-stage peptide, monoclonal, siRNA, and small molecule programs. Key contributor to FIH-Phase 3, DDI, ADME, biopharmaceutic, and special population study protocols and CSRs. Worked in neurology, endocrine, and cardiovascular disease areas with increasing emphasis in oncology. Served as functional area representative on cross-functional program teams and at regulatory meetings. Managed group with Ph.D. level staff.
Mark Stroh Skills
Mark Stroh Education Details
-
Cornell UniversityChemical Engineering -
University Of California, BerkeleyChemical Engineering
-
Harvard Medical SchoolPostdoctoral Fellow
Frequently Asked Questions about Mark Stroh
What company does Mark Stroh work for?
Mark Stroh works for Metsera
What is Mark Stroh's role at the current company?
Mark Stroh's current role is SVP | Head Translational and Quantitative Clinical Pharmacology | Cross Functional Leader | Biotech | Driving pre-IND Through Late-Stage Development | San Francisco, CA | Cambridge, MA.
What is Mark Stroh's email address?
Mark Stroh's email address is ms****@****omx.com
What is Mark Stroh's direct phone number?
Mark Stroh's direct phone number is +180561*****
What schools did Mark Stroh attend?
Mark Stroh attended Cornell University, University Of California, Berkeley, Harvard Medical School.
What skills is Mark Stroh known for?
Mark Stroh has skills like Drug Development, Pharmacokinetics, Pharmacodynamics, Drug Discovery, Clinical Development, Clinical Pharmacology, Pharmaceutical Industry, Drug Metabolism, Pharmacology, Mathematical Modeling, Biomarkers, Monoclonal Antibodies.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial